Colorectal Cancer

In a recent study, researchers observed an independent, dose-response relationship between proton pump inhibitor use and COVID-19 risk. It was the top story in gastroenterology last week.

Use of renin-angiotensin-aldosterone system, or RAAS, antagonists such as ACE inhibitors or angiotensin receptor blockers was linked to reduced risk for colorectal cancer in the 3 years after an index colonoscopy with negative diagnosis.

There was a sustained reduction in mortality among individuals who complied with biennial fecal occult blood test screening for colorectal cancer, according to research published in Clinical Gastroenterology and Hepatology.

According to projections from the National Cancer Institute, COVID-19 will result in 10,000 additional deaths due to breast cancer and colorectal cancer over the next 10 years. This was the top story in hematology/oncology last week.

Adding artificial intelligence systems during colonoscopies helped increase the detection of colorectal neoplasia, according to a meta-analysis published in Gastrointestinal Endoscopy.

The FDA approved pembrolizumab for first-line treatment of patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient colorectal cancer.

In a large cohort study of 33,000 participants, severity of obstructive sleep apnea was independently associated with incident cancer, according to data scheduled for presentation at the American Thoracic Society International Conference.

The COVID-19 pandemic will result in nearly 10,000 additional deaths due to breast cancer and colorectal cancer over the next decade, according to NCI projections.

A computer-aided system helped reduce the number of missed adenomas and missed polyps during colonoscopy, according to study results.

The FDA granted fast track designation to fruquintinib for treatment of certain patients with metastatic colorectal cancer.